Cytestrol acetate

From Wikipedia, the free encyclopedia
Cytestrol acetate
Cytestrol acetate.svg
Clinical data
Other names11α-Hydroxyethinylestradiol 3-(bis(2-chloroethyl)carbamate) 11α,17β-diacetate; 17α-Ethynylestra-1,3,5(10)-triene-3,11α,17β-triol 11α,17β-diacetate 3-(bis(2-chloroethyl)carbamate)
Identifiers
  • (1S,10S,11S,14R,15S,17R)-17-(Acetyloxy)-5-{[bis(2-chloroethyl)carbamoyl]oxy}-14-ethynyl-15-methyltetracyclo[8.7.0.02,7.011,15]heptadeca-2,4,6-trien-14-yl acetate
ChemSpider
Chemical and physical data
FormulaC29H35Cl2NO6
Molar mass564.50 g·mol−1
3D model (JSmol)
  • [H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)C[C@@H](OC(C)=O)[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H]
InChI
  • InChI=1S/C29H35Cl2NO6/c1-5-29(38-19(3)34)11-10-24-23-8-6-20-16-21(37-27(35)32(14-12-30)15-13-31)7-9-22(20)26(23)25(36-18(2)33)17-28(24,29)4/h1,7,9,16,23-26H,6,8,10-15,17H2,2-4H3/t23-,24-,25+,26+,28-,29-/m0/s1
  • Key:RRJRVDYYFLBGSE-UPRLNUCLSA-N

Cytestrol acetate is a steroidal antiestrogen and a cytostatic antineoplastic agent (i.e., chemotherapeutic) which was developed for the treatment of breast cancer but was never marketed.[1][2][3][4] It is an 11α-hydroxylated derivative of ethinylestradiol in which a bis(2-chloroethyl)amine nitrogen mustard moiety has been attached as an ester at the C3 position and acetate esters have been attached at the C11α and C17β positions.[1][2][3][4] The mechanism of action of cytestrol acetate in breast cancer is two-fold: (1) acting as an antiestrogen similarly to fulvestrant or ICI-164384; and (2) having cytostatic actions via the carbamate–nitrogen mustard moiety analogously to estramustine phosphate.[1][2][3][4] The drug shows potent efficacy against breast cancer superior to that of tamoxifen in in vitro models.[1][2][3]

See also[]

References[]

  1. ^ a b c d Oborotov, A. V.; Smirnova, Z. S.; Osetrova, I. P.; Polozkova, A. P.; Rzheznikov, V. M. (1999). "Antitumor activity of various medicinal forms of the new estrogenocytostatic drug cytestrol acetate". Pharmaceutical Chemistry Journal. 33 (10): 526–527. doi:10.1007/BF02508372. ISSN 0091-150X. S2CID 5550495.
  2. ^ a b c d Smirnova ZS, Rzheznikov VM, Tolkachev VN, Borisova LM, Kiseleva MP, Semeĭkin AV, Fedotcheva TA, Shirokikh KE, Banin VV, Shimanovskiĭ NL (2014). "[Antitumor and antiproliferative action of the steroidal cytostatic antiestrogen cytestrol acetate on hormone-dependent tumor models]". Eksp Klin Farmakol (in Russian). 77 (10): 31–5. PMID 25518525.
  3. ^ a b c d Smirnova Z. S, (2003). [Experimental Study of Hormonocytostatics for Treatment of Breast Cancer.] Российский биотерапевтический журнал, 2(2).
  4. ^ a b c Смирнова, З. С., Ржезников, В. М., Толкачев, В. Н., Борисова, Л. М., Киселева, М. П., Семейкин, А. В., ... & Шимановский, Н. Л. (2014). Противоопухолевое и антипролиферативное действие стероидного антиэстрогена цитэстрола ацетата на моделях гормонозависимых опухолей. Экспериментальная и клиническая фармакология, 77(10), 31-35.
Stub icon

This article about a steroid is a stub. You can help Wikipedia by .

  • v
  • t
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""